AU2001291049A1 - Defensin-antigen fusion proteins - Google Patents

Defensin-antigen fusion proteins

Info

Publication number
AU2001291049A1
AU2001291049A1 AU2001291049A AU9104901A AU2001291049A1 AU 2001291049 A1 AU2001291049 A1 AU 2001291049A1 AU 2001291049 A AU2001291049 A AU 2001291049A AU 9104901 A AU9104901 A AU 9104901A AU 2001291049 A1 AU2001291049 A1 AU 2001291049A1
Authority
AU
Australia
Prior art keywords
defensin
fusion proteins
antigen fusion
antigen
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001291049A
Inventor
Arya Biragyn
Larry W Kwak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2001291049A1 publication Critical patent/AU2001291049A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001291049A 2000-09-15 2001-09-17 Defensin-antigen fusion proteins Abandoned AU2001291049A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23307400P 2000-09-15 2000-09-15
US60/233,074 2000-09-15
PCT/US2001/029074 WO2002022686A2 (en) 2000-09-15 2001-09-17 Defensin-antigen fusion proteins

Publications (1)

Publication Number Publication Date
AU2001291049A1 true AU2001291049A1 (en) 2002-03-26

Family

ID=22875781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001291049A Abandoned AU2001291049A1 (en) 2000-09-15 2001-09-17 Defensin-antigen fusion proteins

Country Status (3)

Country Link
US (6) US7754676B2 (en)
AU (1) AU2001291049A1 (en)
WO (1) WO2002022686A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
AU2001291049A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
AU2002217820A1 (en) * 2001-09-17 2003-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection
US7067621B2 (en) * 2002-08-20 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Multifunctional context-activated protides and methods of use
WO2004054603A2 (en) * 2002-12-13 2004-07-01 Case Western Reserve University Use of beta-defensins for treating hiv infections
US7442375B2 (en) 2002-12-13 2008-10-28 Case Western Reserve University Compositions of beta-defensin inducing agents
WO2004055041A2 (en) 2002-12-13 2004-07-01 Case Western Reserve University Defensin-inducing peptides from fusobacterium
WO2004069863A2 (en) * 2003-02-04 2004-08-19 New York University Constrained hiv v3 loop peptides as immunogens and receptor antagonists
US7875598B2 (en) 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
EP1674077A1 (en) * 2004-12-27 2006-06-28 Université de Liège Mucoadhesive pharmaceutical compositions comprising chemoattractants
EP2392647A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007133373A2 (en) * 2006-05-01 2007-11-22 England Robert L TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α
CA2957056A1 (en) 2006-09-06 2008-03-13 C3 Jian, Inc. Selectively targeted antimicrobial peptides and the use thereof
CN101970685B (en) * 2007-01-16 2013-08-07 Musc研究发展基金会 Kit for diagnosing prostate conditions
US9248312B2 (en) 2007-10-26 2016-02-02 Accuray Incorporated Automatic correlation modeling of an internal target
WO2010042644A2 (en) * 2008-10-07 2010-04-15 Biovest International, Inc. Methods for inducing a sustained immune response againts a b-cell idiotype using autologous anti-idiotypic vaccines
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
CN102552306B (en) * 2010-12-13 2015-04-08 马鞍山国声生物技术有限公司 Small molecule interference RNA for reducing antibacterial peptide yield of neutrophils
WO2014028644A1 (en) * 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
US9725768B2 (en) 2012-08-31 2017-08-08 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines
US20150344537A1 (en) * 2013-01-11 2015-12-03 Mark C. Herzberg Non-Transgene Transfection for Therapeutic Purposes
WO2015138494A1 (en) * 2014-03-10 2015-09-17 Georges Belfort Anti-microbial peptides and method for designing novel anti-microbial peptides
EP3125931A4 (en) * 2014-04-03 2017-09-20 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
EP4146258A1 (en) * 2020-05-08 2023-03-15 Intravacc B.V. Click omvs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3710796A (en) 1971-05-14 1973-01-16 C Neefe Corneal drug delivery method
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US6001649A (en) * 1990-11-29 1999-12-14 Societe Anonyme: Elf Sanofi Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
WO1997035008A1 (en) 1996-03-21 1997-09-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chimeric polypeptides for tumor antigen vaccines
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
AU741663B2 (en) * 1996-08-22 2001-12-06 Magainin Pharmaceuticals, Inc. Compositions and methods for use of defensin
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
AU2903999A (en) 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
WO2000078334A1 (en) 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
AU2001291049A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
AU2001291050A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins

Also Published As

Publication number Publication date
US7754676B2 (en) 2010-07-13
US20120134954A1 (en) 2012-05-31
US20050095257A1 (en) 2005-05-05
US20110135715A1 (en) 2011-06-09
US7915040B2 (en) 2011-03-29
US8551936B2 (en) 2013-10-08
US8084250B2 (en) 2011-12-27
US20140234362A1 (en) 2014-08-21
WO2002022686A3 (en) 2003-03-13
WO2002022686A2 (en) 2002-03-21
US8754030B2 (en) 2014-06-17
US20140004113A1 (en) 2014-01-02
US20100260793A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
AU2001262942A1 (en) Albumin fusion proteins
AU2001291049A1 (en) Defensin-antigen fusion proteins
AU2002364586A1 (en) Albumin fusion proteins
AU2002364587A1 (en) Albumin fusion proteins
AU2002307255A1 (en) Vegf fusion proteins
AU3562299A (en) Inhibin-hbc fusion protein
AU2002332041A1 (en) Albumin fusion proteins
AU6045900A (en) Interaction-activated proteins
GB9913437D0 (en) Fusion proteins
AU2001284418A1 (en) Novel polypeptide
AU2001255320A1 (en) Secreted proteins
AU2001291050A1 (en) Viral chemokine-tumur antigen fusion proteins
AU2002232707A1 (en) Transmembrane proteins
AU2002305903A1 (en) Carbohydrate-associated proteins
AU2001290641A1 (en) Substituted fused pyrroleimines and pyrazoleimines
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001244863A1 (en) Apoptin-associating protein
AU2002229675A1 (en) Selective cytotoxic fusion proteins
AU2001260633A1 (en) Fas ligand-fused proteins
AU6983000A (en) Chimeric proteins
AU2001229366A1 (en) Secreted proteins
AU2002224379A1 (en) Clasp-2 transmembrane proteins
AU2002240889A1 (en) Proteins that interact with betatrcp
AU2001241044A1 (en) Mitf-associated proteins
AU2001278777A1 (en) Irap-binding protein